Bayer AGXTER:BAYN +2.56%62 EV-to-FCF is 25.60 as of Jun. 25, 2026, which is 110% above its 10-year median of 12.18. GuruFocus rates XTER:BAYN with a GF Score™ of 62/100 and a GF Value™ of €27.37 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 562 Drug Manufacturers companies, Bayer AG ranks worse than 55.69% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bayer AG's Enterprise Value is €67,608 Mil.
Bayer AG's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €2,641 Mil. Therefore, Bayer AG's EV-to-FCF for today is 25.60.
The historical rank and industry rank for Bayer AG's EV-to-FCF or its related term are showing as below:
XTER:BAYN'
s EV-to-FCF Range Over the Past 10 Years
Min: -140.94 Med: 12.18 Max: 4266.26
Current: 24.95
During the past 13 years, the highest EV-to-FCF of Bayer AG was 4266.26. The lowest was -140.94. And the median was 12.18.
XTER:BAYN's EV-to-FCF is ranked worse than 55.69% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.16
vs XTER:BAYN: 24.95
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bayer AG's share price for today is €39.59.
Bayer AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.190.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bayer AG EV-to-FCF Related Terms
Bayer AG EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bayer AG's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Bayer AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayer AG EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bayer AG's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bayer AG's EV-to-FCF falls into.
Bayer AG's current Enterprise Value is €67,608 Mil.
Bayer AG's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2,641 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bayer AG (XTER:BAYN) has a EV-to-FCF of 25.60 as of Jun. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bayer AG and its competitors. This is 110% above median its historical median of 12.18. According to the industry distribution chart, Bayer AG ranks #313 out of 562 companies in the Drug Manufacturers industry, placing it in the top 55.7%.
Is Bayer AG's EV-to-FCF too high?
Bayer AG's current EV-to-FCF of 25.60 is 110% above median its 10-year median of 12.18. The Drug Manufacturers industry median EV-to-FCF is 20.16. Bayer AG's value of 25.60 is 27% above this industry median. Based on the distribution chart, Bayer AG ranks #313 out of 562 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bayer AG has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's EV-to-FCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #313 out of 562 companies for EV-to-FCF. This places Bayer AG in the lower half of its industry. The industry median EV-to-FCF is 20.16. Bayer AG's value of 25.60 is 27% above this benchmark. While the company's 10-year median is 12.18 vs. the industry median of 20.16, Bayer AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.16, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bayer AG's current EV-to-FCF of 25.60 is 27% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bayer AG and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bayer AG's current EV-to-FCF is 25.60, which is 110% above median its own 10-year median of 12.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XTER:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is €27.37, compared to a current price of €39.59 — trading 44.6% above its estimated fair value. The current EV-to-FCF is 25.60, which is 110% above median its 10-year median of 12.18 and 27% above the Drug Manufacturers industry median of 20.16. Bayer AG's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bayer AG (XTER:BAYN), the current EV-to-FCF is 25.60 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (XTER:BAYN) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of €39.59 is trading 44.6% above its estimated GF Value™ of €27.37.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for XTER:BAYN:
EV-to-FCF: 25.60 (110% above median its 10-year median of 12.18)
GF Value™: €27.37 vs. price of €39.59 (44.6% above fair value)
Industry Position: 27% above the Drug Manufacturers median (#313 of 562)
No single metric tells the full story. See the XTER:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
62GF Score
Get the complete analysis for XTER:BAYN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:BAYN has been successfully added to your 
